SOUTH SAN FRANCISCO, Calif.,
Aug. 23, 2021 /PRNewswire/ -- Vaxart,
Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's
board of directors. Dr. Cherrington is an experienced life science
executive with extensive insights into taking drugs through the
development process to commercialization.
Vaxart is a clinical-stage biotechnology company developing oral
vaccines that are administered by tablet rather than by injection.
Vaxart is now developing oral tablet vaccines for COVID-19 and
norovirus that have the potential to transform public health.
"We are proud to welcome Dr. Julie
Cherrington to the Vaxart Board of Directors," said Vaxart
Board Chairman Todd C. Davis. "She
has had a high-caliber career in life sciences and is the leader of
a cutting-edge clinical stage biotech company. We look forward to
working with her and benefitting from her experience and
wisdom."
"Dr. Cherrington's background in virology and immunology and her
record as the CEO of multiple companies makes her a great fit for
Vaxart, which is pioneering revolutionary oral vaccines," said
Andrei Floroiu, Vaxart's Chief
Executive Officer. "As Vaxart prepares to start our Phase II
COVID-19 oral tablet trials and progress through clinical trials
some of our other programs, we will benefit from Julie's invaluable
insight and experience."
"I am pleased to be joining Vaxart at this critical stage of
company growth and to serve on the Vaxart Board of Directors as the
company continues to advance its oral COVID-19 and norovirus
vaccines in the clinic," said Dr. Cherrington.
Dr. Cherrington's biography can be found below:
Julie M. Cherrington,
Ph.D.
Chief Executive Officer
Julie M Cherrington, Ph.D., is the Chief Executive Officer of
QUE Oncology, a clinical stage company developing novel
non-hormonal treatments for vasomotor symptoms in postmenopausal
women and in cancer patients receiving hormone therapy, a position
she has held since September 2020.
She has served on the QUE Board of Directors since July 2019. Dr. Cherrington is an experienced life
science executive with extensive insight in bringing drugs into the
clinic and through to commercialization. She has been a key
contributor to the successful development of multiple FDA-approved
products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and
HEPSERA®.
Dr. Cherrington has previously served as President and Chief
Executive Officer of several oncology companies including Arch
Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway
Therapeutics. In addition, she served as President and Executive
Vice President, R&D, at Phenomix Corporation, a diabetes and
antiviral company. Earlier in her career, Dr. Cherrington was Vice
President of Preclinical and Clinical Research at SUGEN, a
Pharmacia/Pfizer company. Dr. Cherrington began her career at
Gilead Sciences, where she held a range of positions of increasing
responsibility.
Dr. Cherrington holds a B.S. in biology and an M.S. in
microbiology from the University of
California, Davis. She earned a Ph.D. in microbiology and
immunology from the University of
Minnesota and Stanford
University. She completed a postdoctoral fellowship at the
University of California, San
Francisco.
Dr. Cherrington is a member of the Scientific Advisory Board of
the Clearity Foundation and is an advisor in entrepreneurship
initiatives at CLS, UC San Francisco, UC Davis and Equalize 2020
and 2021. Currently, she serves on the Boards of Sardona
Therapeutics, Rakovina Therapeutics, KisoJi Biotechnology, QUE
Oncology, and Mirati Therapeutics.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a
range of oral recombinant vaccines based on its proprietary
delivery platform. Vaxart vaccines are designed to be administered
using tablets that can be stored and shipped without refrigeration
and eliminate the risk of needle-stick injury. Vaxart believes that
its proprietary tablet vaccine delivery platform is suitable to
deliver recombinant vaccines, positioning the company to develop
oral versions of currently marketed vaccines and to design
recombinant vaccines for new
indications. Vaxart's development programs currently
include tablet vaccines designed to protect against coronavirus,
norovirus, seasonal influenza, and respiratory syncytial virus
(RSV), as well as a therapeutic vaccine for human papillomavirus
(HPV), Vaxart's first immuno-oncology indication. Vaxart
has filed broad domestic and international patent applications
covering its proprietary technology and creations for oral
vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding Vaxart's strategy, prospects, plans and
objectives, results from pre-clinical and clinical trials,
commercialization agreements and licenses, and beliefs
and expectations of management are forward-looking statements.
These forward-looking statements may be accompanied by such words
as "should," "believe," "could," "potential," "will," "expected,"
"plan," and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the receipt by Vaxart's ability to
develop and commercialize its product candidates, including its
vaccine booster products; Vaxart's expectations
regarding clinical results and trial
data; and Vaxart's expectations with respect to the
effectiveness of its product candidates. Vaxart may not actually
achieve the plans, carry out the intentions, or meet the
expectations or projections disclosed in the forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations, and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that
Vaxart makes, including uncertainties inherent in research and
development, including the ability to meet anticipated
clinical endpoints, commencement, and/or completion dates for
clinical trials, regulatory submission dates, regulatory
approval dates, and/or launch dates, as well as the possibility of
unfavorable new clinical data and further analyses of existing
clinical data; the risk that clinical trial data are subject to
differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from the clinical studies; decisions by
regulatory authorities impacting labeling, manufacturing processes,
and safety that could affect the availability or commercial
potential of any product candidate, including the possibility
that Vaxart's product candidates may not be approved by
the FDA or non-U.S. regulatory authorities; that, even if approved
by the FDA or non-U.S. regulatory
authorities, Vaxart's product candidates may not achieve
broad market acceptance; that a Vaxart collaborator may not attain
development and commercial milestones; that Vaxart or its partners
may experience manufacturing issues and delays due to events
within, or outside of, Vaxart's or its partners' control;
difficulties in production, particularly in scaling up initial
production, including difficulties with production costs and
yields, quality control, including stability of the product
candidate and quality assurance testing, shortages of qualified
personnel or key raw materials, and compliance with strictly
enforced federal, state, and foreign regulations; that Vaxart may
not be able to obtain, maintain, and enforce necessary patent and
other intellectual property protection;
that Vaxart's capital resources may be
inadequate; Vaxart's ability to resolve pending legal
matters; Vaxart's ability to obtain sufficient capital to
fund its operations on terms acceptable to Vaxart, if at all; the
impact of government healthcare proposals and policies; competitive
factors; and other risks described in the "Risk Factors" sections
of Vaxart's Quarterly and Annual Reports filed with the
SEC. Vaxart does not assume any obligation to update any
forward-looking statements, except as required by
law.
Contact
Vaxart Media Relations:
Mark Herr
Vaxart, Inc.
(203) 517-8957
mherr@vaxart.com
Vaxart Investor Relations
IR@Vaxart.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vaxart-announces-highly-regarded-biotech-executive-julie-m-cherrington-phd-joins-board-of-directors-301360572.html
SOURCE Vaxart, Inc.